Related Experiment Videos
Controlling hypertension in diabetes
1Steno Diabetes Center, Gentofte, Denmark.
Insights
Type 2 diabetes patients with high blood pressure face significant cardiovascular and kidney risks. Aggressive blood pressure control, often requiring combination therapy with ACE inhibitors and other antihypertensives, is crucial for managing these risks.
Area of Science:
- Cardiology
- Endocrinology
- Nephrology
Background:
- Type 2 diabetes (T2D) patients are highly susceptible to vascular damage from hypertension.
- The co-occurrence of hypertension and T2D elevates the risk of cardiovascular events and end-stage renal disease.
- Established antihypertensive therapies, including ACE inhibitors and CCBs, show benefits in T2D patients.
Purpose of the Study:
- To review the established benefits of antihypertensive therapies in T2D patients.
- To emphasize the importance of aggressive blood pressure lowering in this population.
- To recommend combination therapy for achieving target blood pressure levels.
Main Methods:
- Review of placebo-controlled trials and major clinical trials.
- Analysis of data from the UK Prospective Diabetes Study.
- Evaluation of treatment strategies for hypertensive patients with T2D.
Main Results:
- Antihypertensive drugs (ACE inhibitors, CCBs) demonstrate therapeutic benefits in T2D.
- Aggressive blood pressure lowering significantly reduces T2D complications, as shown in the UK Prospective Diabetes Study.
- Monotherapy often fails to achieve recommended blood pressure targets (<130/85 mm Hg).
Conclusions:
- Combination therapy, particularly ACE inhibitors with CCBs, diuretics, or beta-blockers, is recommended for hypertensive T2D patients.
- Tight blood pressure control is essential for mitigating diabetes-related complications.
- Multidrug regimens are necessary for achieving optimal blood pressure management in T2D.
Abstract:
Patients with type 2 diabetes are especially vulnerable to both large and small vessel injury from elevated arterial blood pressure. The frequent combination of hypertension and diabetes is, therefore, associated with a high risk of cardiovascular events and end-stage renal disease. The beneficial therapeutic effects of angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers (CCBs), and other antihypertensive drugs in patients with type 2 diabetes have been well established in placebo-controlled trials, and there appears to be no evidence of differences between treatment regimens based on different drug classes. In addition, a number of major clinical trials have supported a policy of aggressive blood pressure lowering in patients with type 2 diabetes. In the UK Prospective Diabetes Study, for example, tight control of blood pressure was demonstrated to produce clinically important reductions in the risk of complications related to type 2 diabetes compared with less tight control. In most hypertensive patients, however, a reduction to a recommended level <130/85 mm Hg is unlikely to be achieved by monotherapy. Consequently, the combination of ACE inhibitors with other first-line drugs, such as CCBs, diuretics and beta-blockers, is recommended for the therapeutic management of hypertensive diabetic patients.